Communication

Asymmetric Synthesis of (#)-Incarvillateine Employing an Intramolecular Alkylation via Rh-Catalyzed Olefinic C#H Bond Activation

Andy S. Tsai, Robert G. Bergman, and Jonathan A. Ellman

J. Am. Chem. Soc., **2008**, 130 (20), 6316-6317 • DOI: 10.1021/ja8012159 • Publication Date (Web): 29 April 2008



More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Links to the 3 articles that cite this article, as of the time of this article download
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

View the Full Text HTML

J|A|C|S
COMMUNICATIONS

Published on Web 04/29/2008

Asymmetric Synthesis of (−)-Incarvillateine Employing an Intramolecular Alkylation via Rh-Catalyzed Olefinic C−H Bond Activation

Andy S. Tsai, Robert G. Bergman,* and Jonathan A. Ellman*

Department of Chemistry, University of California, Berkeley, California 94720

Received February 18, 2008; E-mail: bergman@cchem.berkeley.edu; jellman@uclink.berkeley.edu

(−)-Incarvillateine, (−)-**1**, is a monoterpene alkaloid that has attracted attention due to its potent analgesic properties.[1] The first enantioselective synthesis of this natural product was recently achieved[2] but required a number of steps to correctly set the stereochemistry of the five contiguous stereocenters on the bicyclic piperidine moiety.[3] Herein, we report a concise asymmetric synthesis of (−)-incarvillateine employing an intramolecular alkylation of an olefinic C−H bond to set two of the stereocenters with simultaneous stereospecific introduction of an exocyclic, tetrasubstituted alkene framework upon which the bicyclic piperidine could rapidly be assembled.[4−6]



(−)-**1**

(−)-Incarvillateine may be retrosynthetically disconnected to cyclobutane **2** and piperidine **3** (Scheme 1). The synthesis of **2** can be accomplished in two steps from commercially available ferulic acid.[2] Piperidine **3** can be obtained from **4** through reduction of the imine, lactamization, and reduction of both the lactam and alkene. Cyclopentane **4** should be accessible in a key step by the intramolecular alkylation of **5** via Rh-catalyzed C−H activation[7] followed by *syn*-alkene insertion and reductive elimination to exclusively provide the desired exocyclic double bond geometry and the anti relationship of the methyl and ester functionalities. Furthermore, the secondary TBS ether should result in diastereoselective alkylation to install the correct absolute stereochemistry at the methyl and ester stereocenters.

Asymmetric allylation of commercially available **6** with allyltributyltin under Keck conditions proceeded in quantitative yield and with excellent enantioselectivity (Scheme 2).[8] The resulting alcohol was subsequently protected as a TBS ether (**7**). Cross metathesis of **7** with methacrolein using Grubbs' second generation catalyst provided **8** in good yield as a single isomer.[9] Imine **5** was then formed through condensation of **8** with methylamine in the presence of molecular sieves.

The diastereoselective intramolecular alkylation of **5** was explored using conditions recently reported for the intermolecular β-alkenylation of α,β-unsaturated imines with alkynes (Table 1).[10] Ferrocenyl (Fc) dialkyl phosphines (entries 1 and 2) as well as 4-(dimethylamino)phenyl (DMAPh) based phosphines (entries 3−8) were evaluated. Though many of the ligands explored were active, resulting in quantitative cyclization of **5**, (DMAPh)-PEt_2 was the most selective ligand, providing diastereomers **4** and **9** in a ∼5:1 ratio (entry 7).[11] The high catalyst activity also allowed the catalyst loading to be reduced to 2.5 mol % (entry 8).

Due to facile tautomerization of **4** to the ester conjugated dienamine, it was necessary to directly convert the crude compound to a more stable intermediate. This was accomplished through imine reduction with $NaBH_4$ followed by lactamization upon heating to provide **10**, which after chromatography was isolated as a single diastereomer in 49% overall yield from **5** (Scheme 3). Hydrogenation of the tetrasubstituted olefin required high pressure and elevated temperature but occurred exclusively on the less hindered face to yield **11**. Reduction of **11** with $LiAlH_4$, followed by cleavage of the TBS protecting group under acidic conditions, gave **3**.

Scheme 1. Retrosynthesis of (−)-Incarvillateine



Scheme 2. Synthesis of α,β-Unsaturated Imine **5**



Table 1. Ligand Screen for the Diastereoselective Cyclization of **5**



entry	ligand	% Rh	% L	*T* (°C)	*t* (h)	**4** + **9** (%)[a]	**4**:**9** dr[b]
1	$FcPCy_2$	5	11	45	25	100	53:47
2	$FcPEt_2$	5	11	25	21	100	69:31
3	$(DMAPh)_2PMe$	10	22	25	8	100	75:25
4	$(DMAPh)PMe_2$	10	22	45	19	100	75:24
5	$(DMAPh)PCy_2$	5	11	45	21	34	62:38
6	$(DMAPh)PEt_2$	5	11	22	54	100	86:14
7	$(DMAPh)PEt_2$	5	11	45	6	100	83:17
8	**$(DMAPh)PEt_2$**	**2.5**	**5.5**	**45**	**6**	**100**	**83:17**

[a] Yields based on ^1H NMR integration relative to residual protio toluene as an internal standard. [b] Diastereomeric ratio determined by ^1H NMR. Fc: ferrocenyl. DMAPh: 4-(dimethylamino)phenyl.

10.1021/ja8012159 CCC: $40.75

Scheme 3. Synthesis of Bicyclic Piperidine **3**



Table 2. Mitsunobu Coupling of Model Substrate



entry	reagents	*T* (°C)	solvent	% **11**[a]
1	DEAD, PPh_3	65	THF	36
2	DEAD, PPh_3	0	THF	61
3	**DEAD, PPh_3**	**−20**	**THF**	**72**
4	DEAD, PPh_3	25	dioxane	29
5	DEAD, PPh_3	0	CH_2Cl_2	33
6	ADDP, PBu_3	65	toluene	28
7	ADDP, PBu_3	25	THF	0

[a] Isolated yield based on 2-methylcyclopentanol. DEAD: (diethyl diazocarboxylate). ADDP: (1,1′-(azodicarbonyl)dipiperidine).

Completion of the synthesis of (−)-incarvillateine was carried out in accordance with the previously reported sequence: Mitsunobu coupling between **3** and **2** followed by removal of the tosyl protecting groups.[2] The low reported yield in the Mitsunobu coupling reaction (30% based on the more valuable fragment **3**) encouraged us to optimize this step. Commercially available *trans*-2-methylcyclopentanol (**12**) was used as the model substrate for **3** (Table 2). In addition to DEAD/PPh_3 (entries 1−5), ADDP (1,1′-(azodicarbonyl)dipiperidine)/PBu_3[12] was evaluated but showed diminished reactivity (entries 6 and 7). A range of temperatures and solvents was also investigated. Refluxing conditions reported in the prior synthesis were found to be unnecessary and in fact resulted in reduced yield for the model system (entry 1). Dioxane and CH_2Cl_2 were found to be poor solvents for the reaction due to limited solubility of **2** at low temperatures (entries 4 and 5). Use of DEAD/PPh_3 at low temperatures in THF provided the highest yield (entry 3).

Employing the optimal Mitsunobu coupling conditions from the model study, **14** was obtained from **2** and **3** in 55% yield (Scheme 4).[13] Alternatives to sodium amalgam for removal of the tosyl protecting groups in **14** were also explored because the yield reported in the literature was not satisfactory (58%).[2] Sodium/anthracene[14] proved to be optimal and provided (−)-incarvillateine (**1**) in high yield (Scheme 4).

In summary, a concise asymmetric synthesis of (−)-incarvillateine was accomplished in 11 steps and 15.4% overall yield representing a substantial improvement over the previously reported

Scheme 4. Synthesis of (−)-Incarvillateine



synthesis.[2,15] The Rh-catalyzed alkylation of **5** simultaneously installed two of the five necessary stereocenters in the bicylic piperidine while also stereospecifically introducing the tetrasubstituted, exocyclic alkene that enabled the rapid assembly of (−)-**1**.

Acknowledgment. This work was supported by NIH Grant GM069559 to J.A.E. and the DOE, Office of Basic Energy Sciences, Chemical Sciences Division, U.S. Department of Energy, under Contract DE-AC03-76SF00098 to R.G.B. We thank Denise A. Colby for ligands and helpful discussions.

Supporting Information Available: Complete experimental details and spectral data for all compounds described. This material is available free of charge via the Internet at http://pubs.acs.org.

References

(1) (a) Chi, Y. M.; Yan, W. M.; Li, J. S. *Phytochemistry* **1990**, *29*, 2376–2378. (b) Chi, Y.; Nakamura, M.; Yoshizawa, T.; Zhao, X. Y.; Yan, W. M.; Hashimoto, F.; Kinjo, J.; Nohara, T.; Sakurada, S. *Biol. Pharm. Bull.* **2005**, *28*, 1989–1991.
(2) (a) Ichikawa, M.; Takahashi, M.; Aoyagi, S.; Kibayashi, C. *J. Am. Chem. Soc.* **2004**, *126*, 16553–16558.
(3) For leading references on syntheses of natural products with structurally related bicyclic piperidines, see: (a) Wrobleski, A.; Sahasrabudhe, K.; Aubé, J. *J. Am. Chem. Soc.* **2004**, *126*, 5475–5481. (b) Taber, D. F.; You, K. K. *J. Am. Chem. Soc.* **1995**, *117*, 5757–5762. (c) Cid, M. M.; Pombo-Villar, E. *Helv. Chim. Acta* **1993**, *76*, 1591–1607.
(4) For leading references on C−C coupling via heteroatom-directed C−H bond activation initiated olefin insertion, see: (a) Kakiuchi, F.; Murai, S. *Acc. Chem. Res.* **2002**, *35*, 826–834. (b) Jun, C.-H.; Lee, J. H. *Pure Appl. Chem.* **2004**, *76*, 577–587. (c) Thalji, R. K.; Ahrendt, K. A.; Bergman, R. G.; Ellman, J. A. *J. Org. Chem.* **2005**, *70*, 6775–6781.
(5) For a general review on transition-metal-catalyzed cycloisomerizations, see: Trost, B. M.; Krische, M. J. *Synlett* **1998**, 1–16.
(6) For other examples of C−H activation in natural product syntheses, see: (a) Wilson, R. M.; Thalji, R. K.; Bergman, R. G.; Ellman, J. A. *Org. Lett.* **2006**, *8*, 1745–1747. (b) Wiedemann, S. H.; Ellman, J. A.; Bergman, R. G. *J. Org. Chem.* **2006**, *71*, 1969–1976. (c) O'Malley, S. J.; Tan, K. L.; Watzke, A.; Bergman, R. G.; Ellman, J. A. *J. Am. Chem. Soc.* **2005**, *127*, 13496–13497. (d) Davies, H. M. L.; Dai, X.; Long, M. S. *J. Am. Chem. Soc.* **2006**, *128*, 2485–2490. (e) Davies, H. M. L.; Manning, J. R. *Nature* **2008**, *451*, 417–424. (f) Wehn, P. M.; Du Bois, J. *J. Am. Chem. Soc.* **2002**, *124*, 12950–12951. (g) Leblanc, M.; Fagnou, K. *Org. Lett.* **2005**, *7*, 2849–2852.
(7) Colby, D. A.; Bergman, R. G.; Ellman, J. A. *J. Am. Chem. Soc.* **2006**, *128*, 5604–5605.
(8) Keck, G. E.; Welch, D. S.; Vivian, P. K. *Org. Lett.* **2006**, *8*, 3667–3670.
(9) (a) Trost, B. M.; Thiel, O. R.; Tsui, H. C. *J. Am. Chem. Soc.* **2003**, *125*, 13155–13164. (b) Chatterjee, A. K.; Morgan, J. P.; Scholl, M.; Grubbs, R. H. *J. Am. Chem. Soc.* **2000**, *122*, 3783–3784.
(10) Colby, D. A.; Bergman, R. G.; Ellman, J. A. *J. Am. Chem. Soc.* **2008**, *130*, 3645–3651.
(11) Alternative hydroxyl protecting groups such as the benzyl ether were also examined but resulted in decreases in both the rate and diastereoselectivity of the Rh-catalyzed alkylation.
(12) Dembinski, R. *Eur. J. Org. Chem.* **2004**, 2763–2772.
(13) The major side product (22%) resulted from competitive amidation of one of the carboxylic acids in **2** with the hydrazine of reduced DEAD.
(14) Suzuki, H.; Unemoto, M.; Hagiwara, M.; Ohyama, T.; Yokoyama, Y.; Murakami, Y. *J. Chem. Soc., Perkin Trans. 1* **1999**, 1717–1723.
(15) The synthesis of racemic **3** has also been reported: Toshio, H. H.; Kaneda, K. *J. Org. Chem.* **2007**, *72*, 6541–6547.

JA8012159